• endocrine
  • Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. (wikipedia.org)
  • The various kinds of cells that can give rise to NETs are present in endocrine glands and are also diffusely distributed throughout the body, most commonly Kulchitsky cells or similar enterochromaffin-like cells, that are relatively more common in the gastrointestinal and pulmonary systems. (wikipedia.org)
  • Although the cellular origin of NETs of the GI tract is uncertain, consistent expression of cytokeratins in NETs and the expression of the caudal-related homeodomain protein 2 (CdX2 protein), an intestinal transcription factor in endocrine tumors of the small intestine, suggests an origin from an epithelial precursor cell. (cancer.gov)
  • Most NETs of the small and large intestines occur sporadically, while others may occur within the background of an inherited neoplasia syndrome such as multiple endocrine neoplasia type 1 (MEN1) or neurofibromatosis type 1 (NF1) (e.g., gastrin-producing G-cell tumors and somatostatin-producing D-cell tumors of the duodenum, respectively). (cancer.gov)
  • Individual carcinoid tumors have specific histologic and immunohistochemical features based on their anatomic location and endocrine cell type. (cancer.gov)
  • Refer to the PDQ summary on Genetics of Endocrine and Neuroendocrine Neoplasias for more information. (cancer.gov)
  • benign
  • Malformations of the lymphatic system are recognized as benign congenital tumors that affect infant and children in the perinatal era. (readbyqxmd.com)
  • Variants can then be further classified as benign (harmless), likely benign, of uncertain significance, likely pathogenic, or pathogenic (disease causing). (uni-bonn.de)
  • treated with ipilimumab
  • I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. (clinicaltrials.gov)
  • metastasis
  • Symptoms such as abdominal or back pain or pressure, diarrhea, indigestion, or yellowing of the skin and whites of the eyes can arise from the effects of a larger PanNET tumor, either locally or at a metastasis. (wikipedia.org)
  • Pancreatic neuroendocrine tumor staging (AJCC) Stage T1 Stage T2 Stage T3 Stage T4 Involvement of nearby lymph nodes - Stage N1 Metastasis - stage M1 In general, treatment for PanNET encompasses the same array of options as other neuroendocrine tumors, as discussed in that main article. (wikipedia.org)
  • Teratoma
  • Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management. (readbyqxmd.com)
  • Computed tomography scan revealed an adrenal mass for which a right open transperitoneal adrenalectomy was performed, and the lesion was diagnosed as mature teratoma on histopathological examination. (readbyqxmd.com)
  • Teratoma is an unusual neoplasm which arises from one or all the three germ layers. (readbyqxmd.com)
  • diagnosis
  • at five years from diagnosis, 65% of those diagnosed are living, though survival varies considerably depending on the type of tumor. (wikipedia.org)
  • Patients must have a tissue diagnosis of any of the following metastatic, well or moderately differentiated, slow growing neuroendocrine tumor and must demonstrate progressive metastatic disease by prior serial computerized tomography (CT) or magnetic resonance imaging (MRI) scans, or have increased symptoms from their tumors while on sandostatin LAR or octreotide. (clinicaltrials.gov)
  • renal
  • Surveillance recommendations include regular screening for both renal and nonrenal manifestations of disease. (uni-bonn.de)
  • VHL-associated renal tumors of 3 cm in size are commonly managed with surgery . (uni-bonn.de)
  • appendix
  • Midgut tumors, which account for up to 50% of cases, arise in the small intestine, appendix, or proximal colon. (cancer.gov)
  • symptoms
  • 3 ] However, it is possible that the association may be due in part to the serendipitous discovery of slow-growing carcinoid tumors, which are found while staging or investigating symptoms from other tumors. (cancer.gov)
  • tissue
  • I. To evaluate the association of tumor mutational burden measured by tissue sequencing with durable response (complete response [CR] or partial response [PR] lasting 24 weeks or more). (clinicaltrials.gov)